Pregabalin controlled-release - GL PharmTech

Drug Profile

Pregabalin controlled-release - GL PharmTech

Alternative Names: GLA5PR; GLA5PR GLARS; GLA5PR GLARS-NF1; GLA5PR GLARS-NF1 Tab; GLA5PR GLARS-NF3; Pregabalin GLARS; Pregabalin QD

Latest Information Update: 24 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GL PharmTech
  • Developer Daewon Pharmaceutical; GL PharmTech
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Neuropathic pain
  • Phase I Pain

Most Recent Events

  • 24 Jul 2017 GL PharmTech has patent protection for oral pregabalin sustained-release triple layer tablet in Japan, European Union and USA, before July 2017 (GL PharmTech website, July 2017)
  • 01 Apr 2017 GL Pharm Tech Corporation completes a phase I bioequivalence trial in Healthy volunteers in South Korea (PO, Tablet) (NCT02952937)
  • 01 Apr 2017 GL Pharm Tech Corporation completes a phase I bioequivalence trial in Healthy volunteers in South Korea (PO, Tablet) (NCT02955472)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top